AI导航下血肿抽吸与保守治疗自发性脑出血的随机对照试验方案
本研究为多中心、前瞻性、随机对照、开放标签、结局评估盲法的试验,计划纳入约680例发病24小时内、血肿量20-50 mL、GCS≥8分的幕上自发性脑出血患者,1:1随机接受AI辅助导航引导下血肿抽吸联合最佳药物治疗或单纯最佳药物治疗,主要结局为6个月mRS 0-2分的功能状态。
要点
- 针对幕上自发性脑出血(20-50 mL)且GCS≥8分、发病24小时内患者。
- AI导航血肿抽吸联合最佳药物治疗对比单纯最佳药物治疗。
- 主要结局为6个月mRS 0-2分的良好功能结局。
核心结论
- 该试验旨在为AI引导下血肿抽吸治疗自发性脑出血的疗效与安全性提供可靠证据,若成功可能支持精准微创治疗策略并改善临床结局。
研究设计与样本
- 多中心、前瞻性、随机对照、开放标签、结局评估盲法的试验,计划纳入约680例自发性幕上脑出血患者。
- 纳入标准:发病24小时内、血肿量20-50 mL、GCS评分≥8分、年龄18-80岁。
- 按1:1比例随机分配至AI辅助导航引导下血肿抽吸联合最佳药物治疗组或单纯最佳药物治疗组,随机化采用中央分层按中心进行。
关键数值与推荐
- 主要结局为6个月时改良Rankin量表(mRS)评估的功能状态,mRS 0-2分定义为良好结局。
- 次要结局包括死亡率、血肿体积减少、神经功能、并发症、生活质量、住院时间和成本效益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Spontaneous intracerebral hemorrhage (ICH) remains one of the most devastating types of stroke, with high mortality and long-term disability. Minimally invasive hematoma evacuation techniques have been developed to improve outcomes by reducing hematoma volume while minimizing surgical trauma compared with conventional craniotomy or conservative treatment. Artificial intelligence (AI) and neuronavigation enable optimized trajectory planning, real-time intraoperative guidance, and individualized treatment strategies, potentially leading to improved clinical outcomes compared with conservative treatment. This study aims to compare the efficacy and safety of AI-driven navigated hematoma aspiration with conservative therapy. METHODS: This multicenter, prospective, randomized controlled, open-label trial with blinded outcome assessment will enroll approximately 680 patients with spontaneous supratentorial ICH (20-50 mL) within 24 h of onset and a Glasgow Coma Scale (GCS) score ≥ 8. Eligible patients aged 18-80 years will be randomly assigned in a 1:1 ratio to receive either AI-assisted, navigation-guided hematoma aspiration plus best medical therapy or best medical therapy alone. Randomization will be centralized and stratified by center. The primary outcome is functional status at 6 months, assessed by the modified Rankin Scale, with mRS 0-2 defined as a favorable outcome. Secondary outcomes include mortality, hematoma volume reduction, neurological function, complications, quality of life, length of hospital stay, and cost-effectiveness. DISCUSSION: This trial is designed to provide robust evidence on the efficacy and safety of AI-guided hematoma aspiration for ICH. If successful, it has the potential to support a precise and minimally invasive treatment strategy and improve clinical outcomes. TRIAL REGISTRATION: Clinical Trials NCT07077343. Registered on July 21, 2025.
引用
- Xu X, Zhang J, Yuan Q, et al. AI-driven navigated hematoma aspiration vs. conservative treatment for spontaneous intracerebral hemorrhage: study protocol for a randomized controlled trial. Trials. 2026. PMID: 42021277. doi:10.1186/s13063-026-09738-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。